Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Journal of Research in Pharmacy and Pharmaceutical Sciences
Roqayyah Said Zubaidy
Jalan Kebon Nanas Selatan II No 09, Jakarta Timur
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Other

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
EFFICACY AND ADVERSE OF EFFECTS MULTI-DRUG RESISTANT PULMONARY TUBERCULOSIS REGIMEN THERAPY A SYSTEMATIC REVIEW FROM RANDOMIZED CONTROL TRIAL Roqayyah Said Zubaidy
Journal of Research in Pharmacy and Pharmaceutical Sciences Vol 4 No 1 (2025): Vol.4 No.1 JUNE (2025)
Publisher : Pharmacy Program, Faculty of Medicine, UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33533/jrpps.v4i2.12417

Abstract

Multidrug-resistant tuberculosis (MDR-TB) remains a major challenge in global tuberculosis control due to low treatment success rates, long therapy durations, and a high risk of adverse effects. The development of new therapy regimens and additional strategies continues to be evaluated to improve treatment efficacy and safety. This systematic literature review was conducted by examining four randomized controlled trials published between 2015 and 2025, namely the studies by Tang et al., Zhang et al., Ruan et al., and Nyang’wa et al. Articles were selected based on their relevance to the topic of efficacy and adverse effects of MDR-TB therapy regimens. Extracted data included culture conversion rates, treatment success, recovery time, and safety profiles. This review shows that innovations in MDR-TB therapy regimens, whether through the addition of new drugs, the use of adjuvant herbal therapies, or the development of short-course oral regimens—can enhance efficacy while improving treatment safety profiles. These findings support the implementation of new regimens as more effective and safer therapeutic alternatives, with the potential to improve patient adherence in MDR-TB management.
Co-Authors